Ugur Sahin, chief executive officer of BioNTech SE ($BNTX), sold 32,000 shares of company stock on September 30, 2026, in an open-market transaction. The shares went at an average price of $98.12 each, for a total sale value of $3,139,849.60. The Form 4 was filed the same day and listed 214,209 shares owned after the transaction.
The September 30 trade was the latest in a series of open-market sales Sahin reported during the month. Across eight transactions dated between September 15 and September 30, he sold a combined 248,000 $BNTX shares for roughly $24.28 million. The run began with a 34,000-share sale on September 15 and ended with the 32,000-share sale on September 30. Per-share prices in the sequence ranged from $96.09 on September 16 to $99.40 on September 23, and the individual sales ranged from 15,000 shares on September 16 to 39,000 shares on September 24. The largest single transaction in the run was the September 24 sale of 39,000 shares for $3,860,660.70. His reported holdings moved from about 602,209 shares before the September 15 sale to 214,209 shares after the September 30 transaction.
The filings in the sequence were submitted promptly. The September 29 and September 30 sales both appeared on a Form 4 dated September 30. The September 23, September 17, and September 15 sales each appeared on a filing dated the following day, while the September 24, September 18, and September 16 sales were reported the same day they occurred.
$BNTX shares closed at $98.57 on September 29, the session before the final sale in the run, and at $98.46 on September 23. Trading during the window also included closes of $100.87 on September 22 and $95.83 on September 16.
$BNTX has also appeared in congressional STOCK Act disclosures, although none overlap with Sahin's September activity. The most recent congressional entry was a sale by Representative Valerie Hoyle in August 2025, disclosed 36 days after the trade date. Representative Josh Gottheimer filed several $BNTX transactions between December 2023 and September 2024, spanning both purchases and sales. Congressional disclosure amounts reflect bracketed ranges rather than exact dollar figures.
Within the September 2026 window, no other $BNTX insiders reported open-market transactions; all eight filings on the ticker for the month were Sahin's sales. Sahin is listed as CEO on the Form 4 filings.